At a glance
ClinicalIndex Comparison RecordN/ACompleted· 18 enrolled
Drug / intervention
42 Gy Radiation Therapy +2 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study of Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers (HART-HN)
In Brief
A clinical study evaluating 42 Gy Radiation Therapy, 39 Gy Radiation Therapy, and 1 other intervention for Resectable Head and Neck Squamous Cell Carcinoma. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The primary purpose of this study is to determine the safe reduction of the treatment fractions to 10, 8, or 5, that may be delivered safely in resected head and neck squamous cell carcinoma (HNSCC) patients with intermediate pathologic risk features.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedNov 2021
Enrollment StartDec 2021
Primary CompletionMar 2025
Study CompletionNov 2025
TodayJul 2026
First PostedNov 16, 2021
Enrollment StartDec 1, 2021
Primary CompletionMar 6, 2025
Study CompletionNov 22, 2025
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 4.6 years ago
Interventions
42 Gy Radiation Therapyradiation
Radiation Therapy: Dose per fraction of 4.2 Gy.
39 Gy Radiation Therapyradiation
Radiation Therapy: Dose per fraction of 4.875 Gy.
32.5 Gy Radiation Therapyradiation
Radiation Therapy: Dose per fraction of 6.5 Gy.